All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Have big data changed the view on AML risk classification?
During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to Lars Bullinger, Charité – Universitätsmedizin Berlin, Berlin, DE. We asked: Have big data changed the view on AML risk classification?
In recent years, the prognostic value of molecular markers has been established, with six already incorporated into the European LeukemiaNet guidelines. This recent compilation of datasets across Europe has provided additional prognostic information and promises to better assist treatment decisions and improve patient outcomes.
Have big data changed the view on AML risk classification?
More about...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox